Shares in Santhera Pharmaceuticals AG rose more than 8 percent Friday on news of a European partnering deal with Ipsen Group SA, worth up to €141 million (US$181 million), for its Parkinson's drug Fipamezole. (BioWorld International)

Karo Bio AB is finalizing the design of a Phase III program for its lead drug candidate, eprotirome (KB2115), which is in development for heterozygous familial hypercholesterolemia (HeFH), a genetic condition characterized by the accumulation of elevated levels of low density lipoprotein (LDL) cholesterol and increased risk of atherosclerosis at an early age. (BioWorld International)